Països Baixos - neerlandès - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

medcor pharmaceuticals b.v. - benserazidehydrochloride samenstelling overeenkomend met; benserazide; levodopa; - tablet - levodopa and decarboxylase inhibitor

Països Baixos - neerlandès - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

medcor pharmaceuticals b.v. artemisweg 232 8239 de lelystad - dornase alfa - verneveloplossing - calciumchloride 2-water (e 509) ; natriumchloride ; water voor injectie - dornase alfa (desoxyribonuclease)

Bèlgica - neerlandès - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

roche sa-nv - levodopa 100 mg; benserazidehydrochloride 28,5 mg - eq. benserazide 25 mg - dispergeerbare tablet - 100 mg - 25 mg - levodopa 100 mg; benserazidehydrochloride 28.5 mg - levodopa and decarboxylase inhibitor

Bèlgica - neerlandès - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

roche sa-nv - levodopa 200 mg; benserazidehydrochloride 57 mg - eq. benserazide 50 mg - tablet - 200 mg - 50 mg - levodopa 200 mg; benserazidehydrochloride 57 mg - levodopa and decarboxylase inhibitor

Bèlgica - neerlandès - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

roche sa-nv - levodopa 100 mg; benserazidehydrochloride 28,5 mg - eq. benserazide 25 mg - capsule met verlengde afgifte, hard - 100 mg - 25 mg - levodopa 100 mg; benserazidehydrochloride 28.5 mg - levodopa and decarboxylase inhibitor

Unió Europea - neerlandès - EMA (European Medicines Agency)

roche registration gmbh - polatuzumab vedotin - lymfoom, b-cel - antineoplastische middelen - polivy in combinatie met bendamustine en rituximab is geïndiceerd voor de behandeling van volwassen patiënten met recidiverende/refractaire diffuus grootcellig b-cel lymfoom (dlbcl) die geen kandidaat zijn voor een hematopoëtische stamceltransplantatie. polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (r-chp) is indicated for the treatment of adult patients with previously untreated diffuse large b-cell lymphoma (dlbcl).

Unió Europea - neerlandès - EMA (European Medicines Agency)

roche registration gmbh  - entrectinib - cancer; carcinoma, non-small-cell lung - antineoplastische middelen - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.

Unió Europea - neerlandès - EMA (European Medicines Agency)

roche registration gmbh - baloxavir marboxil - influenza, human - antivirale middelen voor systemisch gebruik - treatment of influenzaxofluza is indicated for the treatment of uncomplicated influenza in patients aged 1 year and above. post exposure prophylaxis of influenzaxofluza is indicated for post-exposure prophylaxis of influenza in individuals aged 1 year and above. xofluza should be used in accordance with official recommendations.

Unió Europea - neerlandès - EMA (European Medicines Agency)

roche registration gmbh - pertuzumab, trastuzumab - neoplasmata van de borst - antineoplastische middelen - early breast cancer (ebc)phesgo is indicated for use in combination with chemotherapy in:the neoadjuvant treatment of adult patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrencethe adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrencemetastatic breast cancer (mbc)phesgo is indicated for use in combination with docetaxel in adult patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease.

Unió Europea - neerlandès - EMA (European Medicines Agency)

roche registration gmbh  - risdiplam - spier-atrofie, spinale - andere geneesmiddelen voor aandoeningen van het musculo-skeletale systeem - evrysdi is indicated for the treatment of 5q spinal muscular atrophy (sma) in patients with a clinical diagnosis of sma type 1, type 2 or type 3 or with one to four smn2 copies.